$72 Million
Joint Bookrunner
Initial Public Offering
July 2019
$401 Million
Joint Bookrunner
Initial Public Offering
June 2019
$104 Million
Joint Bookrunner
Follow-On
June 2019
$73 Million
Joint Bookrunner
Follow-On
June 2019
$37 Million
Joint Bookrunner
Follow-On
June 2019
$115 Million
Joint Bookrunner
Follow-On
June 2019
$58 Million
Joint Bookrunner
Follow-On
June 2019
$115 Million
Joint Bookrunner
Follow-On
June 2019
$201 Million
Joint Bookrunner
Follow-On
May 2019
$250 Million
Joint Bookrunner
Follow-On
May 2019
$149 Million
Joint Bookrunner
Follow-On
May 2019
$71 Million
Joint Bookrunner
Initial Public Offering
May 2019
$55 Million
Joint Bookrunner
Initial Public Offering
May 2019
$230 Million
Joint Bookrunner
Follow-On
May 2019
$128 Million
Joint Bookrunner
Follow-On
May 2019
$47 Million
Joint Placement Agent
Private Placement
May 2019
$84 Million
Joint Bookrunner
Initial Public Offering
April 2019
$191 Million
Joint Bookrunner
Initial Public Offering
April 2019
$91 Million
Joint Bookrunner
Follow-On
April 2019
$155 Million
Joint Global Coordinator and Bookrunner
Initial NASDAQ Listing
March 2019
$50 Million
Joint Bookrunner
Follow-On
March 2019
Undisclosed
Exclusive Financial Advisor
Merger with Venus Concept
Pending
$197 Million
Joint Bookrunner
Follow-On
March 2019
$160M + $140M Milestones
Exclusive Financial Advisor
Acquisition of Hematology / Oncology Portfolio from Spectrum Pharmaceuticals
March 2019
$98 Million
Sole Bookrunner
Follow-On
February 2019
$170 Million
Joint Bookrunner
Follow-On & Concurrent Private Placement
February 2018
Undisclosed
Exclusive Financial Advisor
Practice Partnership with Radiology Partners
February 2019
$75 Million
Joint Bookrunner
Initial Public Offering
February 2019
$59 Million
Joint Bookrunner
Follow-On
February 2019
$110 Million
Joint Bookrunner
Follow-On
February 2019
$317 Million
Joint Bookrunner
Initial Public Offering
February 2019
$81 Million
Joint Bookrunner
Initial Public Offering
February 2019
Undisclosed
Exclusive Financial Advisor
Sale to Strides Pharma Science Limited
January 2019
$173 Million
Joint Book-Running Manager
Follow-On
January 2019
$265 Million
Joint Bookrunner
Follow-On
January 2019
$40 Million
Sole Bookrunner
Follow-On
December 2018
$45 Million
Joint Bookrunner
Follow-On
December 2018
$30 Million
Joint Bookrunner
Follow-On
December 2018
$151 Million
Joint Bookrunner
Initial Public Offering
December 2018
$100 Million
Joint Bookrunner
Follow-On
December 2018
Undisclosed
Exclusive Financial Advisor
Merger with Mereo BioPharma
Pending
Undisclosed
Exclusive Financial Advisor
Merger with X4 Pharmaceuticals
Pending
$850 Million
Joint Bookrunner
Convertible Senior Notes
November 2018
Undisclosed
Exclusive Financial Advisor
Sale to Convey Health Solutions, a Portfolio Company of NMC
November 2018
$80 Million
Exclusive Financial Advisor
Sale of Priority Review Voucher to Eli Lilly
October 2018
$81 Million
Joint Bookrunner
Follow-On
October 2018
$125 Million + 1 Million Shares
Exclusive Financial Advisor
Acquisition of Genoptix
Pending
$85 Million
Joint Bookrunner
Follow-On
October 2018
$107 Million
Joint Bookrunner
Follow-On
October 2018
$65 Million
Joint Bookrunner
Initial Public Offering
October 2018
$150 Million
Joint Bookrunner
Convertible Senior Notes
October 2018
Undisclosed
Exclusive Financial Advisor
Sale to Teleflex
October 2018
$273 Million
Co-Manager
Initial Public Offering
October 2018
$122 Million
Joint Bookrunner
Initial Public Offering
September 2018
$217 Million
Exclusive Financial Advisor
Sale to Evolent Health
Pending
$115 Million
Joint Bookrunner
Follow-On
September 2018
$150 Million
Joint Bookrunner
Follow-On
September 2018
$144 Million
Joint Bookrunner
Follow-On
August 2018
$312 Million
Joint Bookrunner
Follow-On
August 2018
$59 Million
Joint Bookrunner
Follow-On
July 2018
$248 Million
Joint Bookrunner
Follow-On
July 2018
$116 Million
Joint Bookrunner
Initial Public Offering
July 2018
$99 Million
Joint Bookrunner
Follow-On
July 2018
$277 Million
Joint Bookrunner
Initial Public Offering
July 2018
$117 Million
Joint Bookrunner
Initial Public Offering
July 2018
$166 Million
Joint Bookrunner
Follow-On
July 2018
$70 Million
Sole Bookrunner
Follow-On
July 2018
NZ$255 Million
Financial Advisor
Recapitalization by Hg
Pending
$126 Million
Joint Bookrunner
Initial Public Offering
June 2018
$77 Million
Sole Bookrunner
Follow-On
June 2018
$98 Million
Joint Bookrunner
Initial Public Offering
June 2018
$118 Million
Joint Bookrunner
Initial Public Offering
June 2018
$233 Million
Co-Manager
Convertible Senior Notes
June 2018
$75 Million
Joint Bookrunner
Follow-On
May 2018
$53 Million
Joint Bookrunner
Follow-On
May 2018
$83 Million
Joint Bookrunner
Initial Public Offering
May 2018
$58 Million
Joint Bookrunner
Follow-On
May 2018
$141 Million
Joint Bookrunner
Follow-On
May 2018
$42 Million
Joint Bookrunner
Initial NASDAQ Listing
May 2018
$117 Million
Joint Bookrunner
Follow-On
May 2018
$147 Million
Joint Bookrunner
Follow-On
May 2018
$155 Million
Joint Bookrunner
Follow-On
May 2018
Undisclosed
Exclusive Financial Advisor
Acquisition of Braintree Laboratories
May 2018
Undisclosed
Exclusive Financial Advisor
Sale to Dentsply Sirona Inc.
May 2018
$160 Million
Joint Bookrunner
Convertible Senior Subordinated Notes
April 2018
$239 Million
Joint Bookrunner
Initial NASDAQ Listing
April 2018
$30 Million
Sole Placement Agent
Registered Direct Offering
April 2018
Undisclosed
Exclusive Financial Advisor
Recapitalization by WCAS
April 2018
Undisclosed
Exclusive Financial Advisor
Sale to Boston Scientific
April 2018
$110 Million
Joint Bookrunner
Follow-On
March 2018
$406 Million
Joint Bookrunner
Follow-On
March 2018
$260 Million
Joint Bookrunner
Follow-On
March 2018
Undisclosed
Exclusive Financial Advisor
Sale to JLL Partners and Water Street Healthcare Partners
March 2018
$138 Million
Joint Bookrunner
Initial Public Offering
March 2018
$614 Million
Lead Financial Advisor
Acquisition of Cascadian Therapeutics
March 2018
$314 Million
Co-Bookrunning Manager
Follow-On
February 2018
$144 Million
Lead Bookrunning Manager
Exchangeable Senior Notes
February 2018
$69 Million
Sole Bookrunner
Follow-On
February 2018
$288 Million
Joint Bookrunner
Convertible Senior Notes
January 2018
$144 Million
Joint Bookrunner
Follow-On
January 2018
$147 Million
Joint Bookrunner
Initial Public Offering
January 2018
$144 Million
Joint Bookrunner
Initial Public Offering
January 2018
$98 Million
Joint Bookrunner
Initial Public Offering
January 2018
$231 Million
Joint Bookrunner
Follow-On
January 2018
$115 Million
Joint Bookrunner
Follow-On
January 2018
$143 Million
Joint Bookrunner
Follow-On
January 2018
$58 Million
Joint Bookrunner
Follow-On
January 2018
$450 Million
Joint Bookrunner
Convertible Senior Notes
January 2018
$690 Million
Co-Manager
Convertible Senior Notes
January 2018
$40 Million
Joint Bookrunner
Follow-On
January 2018
$800 Million
Joint Bookrunner
Follow-On
January 2018
$67 Million
Financial Advisor
Private Placement
December 2017
$46 Million
Joint Bookrunner
Follow-On
December 2017
$46 Million
Joint Bookrunner
Follow-On
December 2017
$74 Million
Joint Bookrunner
Initial Public Offering
December 2017
Undisclosed
Exclusive Financial Advisor
Sale to Quest Diagnostics
December 2017
$102 Million
Joint Bookrunner
Initial Public Offering
November 2017
$41 Million
Sole Bookrunner
Follow-On
November 2017
$51 Million
Joint Bookrunner
Secondary Offering
November 2017
$106 Million
Joint Bookrunner
Initial Public Offering
November 2017
$150 Million
Joint Bookrunner
Follow-On
November 2017
$92 Million
Joint Bookrunner
Follow-On
October 2017
$91 Million
Joint Bookrunner
Follow-On
October 2017
Undisclosed
Exclusive Financial Advisor
Acquisition of Tea Leaves Health
October 2017
$69 Million
Joint Bookrunner
Follow-On
October 2017
$108 Million
Joint Bookrunner
Follow-On
October 2017
$289 Million
Joint Bookrunner
Follow-On
October 2017
$86 Million
Joint Bookrunner
Initial Public Offering
September 2017
$172 Million
Joint Bookrunner
Follow-On
September 2017
$230 Million
Joint Bookrunner
Follow-On
September 2017
$173 Million
Joint Bookrunner
Initial Public Offering
September 2017
$161 Million
Joint Bookrunner
Follow-On
September 2017
$403 Million
Joint Bookrunner
Follow-On
September 2017
$375 Million
Joint Bookrunner
Follow-On
August 2017
Undisclosed
Exclusive Financial Advisor
Royalty Restructuring Transaction
August 2017
$330 Million
Exclusive Financial Advisor
Senior Credit Facilities Transaction with PNC & TCP
August 2017
$57 Million
Joint Bookrunner
Follow-On
August 2017
$86 Million
Joint Bookrunner
Follow-On
August 2017
$80 Million
Exclusive Financial Advisor
Acquisition of Exclusive WW Lebrikizumab License from Roche
August 2017
$138 Million
Joint Bookrunner
Initial Public Offering
August 2017
$40 Million
Exclusive Financial Advisor
Acquisition of Good Start Genetics
July 2017
$73 Million
Placement Agent
PIPE
July 2017
$116 Million
Joint Bookrunner
Follow-On
July 2017
$223 Million
Exclusive Financial Advisor
Private Placement
July 2017
$46 Million
Sole Bookrunner
Follow-On
July 2017
$97 Million
Joint Bookrunner
Follow-On
July 2017
$70 MILLION + MILESTONES
Exclusive Financial Advisor
Sale to Cotiviti
July 2017
$173 Million
Joint Bookrunner
Follow-On
July 2017
$173 Million
Joint Bookrunner
Follow-on
July 2017
$86 Million
Joint Bookrunner
Initial Public Offering
June 2017
$75 Million
Joint Bookrunner
Initial Public Offering
June 2017
$41 Million
Sole Bookrunner
Follow-On
May 2017
$113 Million
Joint Bookrunner
Follow-On
May 2017
Undisclosed
Exclusive Financial Advisor
Sale to Apax Partners
May 2017
$288 Million
Joint Bookrunner
Convertible Senior Notes
May 2017
Undisclosed
Exclusive Financial Advisor
Sale to Sheridan Capital Partners
April 2017
$518 Million
Joint Bookrunner
Convertible Senior Notes
April 2017
Undisclosed
Exclusive Financial Advisor
Acquisition of ArroHealth
April 2017
$79 Million
Joint Bookrunner
Follow-On
April 2017
$85 Million
Joint Bookrunner
Initial Public Offering
April 2017
$100 Million
Joint Bookrunner
Follow-On
April 2017
$120 Million
Joint Bookrunner
Follow-On
April 2017
$200 Million
Exclusive Financial Advisor
Sale to Sucampo
April 2017
$1.65 Billion
Exclusive Financial Advisor
Sale to Hologic
March 2017
$349 Million
Co-Manager
Follow-On
March 2017
$66 Million
Joint Bookrunner
Follow-On
March 2017
$81 Million
Sole Bookrunner
Follow-On
March 2017
$173 Million
Joint Bookrunner
Follow-On
March 2017
$194 Million
Joint Bookrunner
Follow-On
March 2017
$97 Million
Joint Bookrunner
Initial Public Offering
January 2017
Undisclosed
Exclusive Financial Advisor
Sale to Zydus Cadila
January 2017
Undisclosed
Exclusive Financial Advisor
Sale to Tailwind Capital
January 2017
$150 Million
Joint Bookrunner
Follow-On
January 2017
$440 Million
Exclusive Financial Advisor
Acquisition of Rights to Palatin Technologies' Rekynda
January 2017
$69 Million
Sole Bookrunner
Follow-On
January 2017
$60 Million
Exclusive Financial Advisor
Equity Investment from KKR
December 2016
$300 Million
Sole Manager
Convertible Senior Notes
December 2016
Undisclosed
Financial Advisor
Sale to Unilever
December 2016
$250 Million
Joint Bookrunner
Convertible Senior Notes
December 2016
$101 Million
Joint Bookrunner
Follow-On
December 2016
$23 Million
Exclusive Placement Agent
Series C Preferred Financing
November 2016
$127 Million
Sole Bookrunner
Follow-On
November 2016
$57 Million
Exclusive Placement Agent
Private Placement
November 2016
$105 Million
Joint Bookrunner
Follow-On
November 2016
$236 Million
Joint Bookrunner
Follow-On
November 2016
$34 Million
Sole Bookrunner
Follow-On
November 2016
$230 Million
Joint Bookrunner
Convertible Notes
October 2016
$115 Million
Joint Bookrunner
Follow-On
October 2016
$169 Million
Co-Manager
Follow-On
September 2016
$76 Million
Joint Bookrunner
Initial Public Offering
September 2016
$75 Million
Joint Bookrunner
Follow-On
September 2016
$33 Million
Joint Bookrunner
Follow-On
September 2016
~$800 Million
Financial Advisor
Sale to Horizon Pharma
Pending
$75 Million
Joint Bookrunner
Follow-On
September 2016
$63 Million
Sole Bookrunner
Follow-On
August 2016
$93 Million
Joint Bookrunner
Initial Public Offering
August 2016
$168 Million
Exclusive Financial Advisor
Convertible Note Exchange
August 2016
$410 Million
Financial Advisor
Sale to Myriad Genetics
August 2016
$32 Million
Joint Bookrunner
Follow-On
July 2016
$719 Million
Co-Manager
Initial Public Offering
July 2016
$35 Million
Sole Bookrunner
Follow-On
July 2016
$433 Million
Joint Bookrunner
Follow-On
June 2016
$150 Million
Co-Manager
Convertible Senior Notes
June 2016
$64 Million
Joint Bookrunner
Follow-On
June 2016
$25 Million
Exclusive Placement Agent
Private Placement
June 2016
$145 Million
Joint Bookrunner
Follow-On
June 2016
$50 Million
Sole Bookrunner
Follow-On
May 2016
$124 Million
Joint Bookrunner
Initial Public Offering
May 2016
$115 Million
Joint Bookrunner
Follow-On
April 2016
$190 Million
Co-Manager
Initial Public Offering
April 2016
$85 Million
Exclusive Financial Advisor
Sale to Allergan
April 2016
Undisclosed
Exclusive Financial Advisor
Sale to Alvogen
April 2016
$144 Million
Joint Bookrunner
Follow-On
April 2016
$49 Million
Joint Bookrunner
Follow-On
March 2016
$185 Million
Exclusive Financial Advisor
Acquisition of US Contrave Rights from Takeda
March 2016
Undisclosed
Exclusive Financial Advisor
European Commercialization Agreement with Valeant
March 2016
$165 Million
Exclusive Financial Advisor
Senior Secured Convertible Notes
March 2016
$50 Million
Joint Bookrunner
Initial Public Offering
February 2016
$410 Million
Exclusive Financial Advisor
Sale of Hemostasis Portfolio to Mallinckrodt plc
February 2016
$86 Million
Joint Bookrunner
Follow-On
January 2016
Undisclosed
Exclusive Financial Advisor
Sale to Consonance Capital Partners
January 2016
$120 Million
Joint Bookrunner
Follow-On
January 2016
$150 Million
Joint Bookrunner
Follow-On
January 2016
$275 Million
Exclusive Financial Advisor
Sale to NeoGenomics Laboratories
December 2015
$34 Million
Co-Manager
Follow-On
December 2015
$50 Million
Exclusive Placement Agent
Private Placement
December 2015
CHF 60 Million
Exclusive Financial Advisor
Private Placement
November 2015
$23 Million
Exclusive Placement Agent
Private Placement
November 2015
$45 Million
Exclusive Financial Advisor
Sale to Abcam plc
November 2015
$102 Million
Joint Bookrunner
Initial Public Offering
November 2015
$50 Million
Joint Bookrunner
Equity Offering
November 2015
$93 Million
Joint Bookrunner
Initial Public Offering
September 2015
$44 Million
Joint Bookrunner
Initial Public Offering
September 2015
$847 Million
Exclusive Financial Advisor
Acquisition of Scioderm
September 2015
$66 Million
Co-Manager
Follow-On
September 2015
$345 Million
Joint Bookrunner
Follow-On
September 2015
$92 Million
Joint Bookrunner
Initial Public Offering
September 2015
$101 Million
Joint Bookrunner
Follow-On
September 2015
$37 Million
Sole Placement Agent
Private Placement
September 2015
$480 Million
Joint Bookrunner
Follow-On
September 2015
$98 Million
Joint Bookrunner
Follow-On
September 2015
$70 Million
Exclusive Placement Agent
Private Placement
August 2015
$42 Million
Exclusive Placement Agent
Private Placement
August 2015
$66 Million
Exclusive Placement Agent
Private Placement
August 2015
$111 Million
Joint Bookrunner
Follow-On
August 2015
$52 Million
Joint Bookrunner
Follow-On
August 2015
$98 Million
Joint Bookrunner
Follow-On
July 2015
$68 Million
Sole Bookrunner
Convertible Senior Notes
July 2015
$55 Million
Exclusive Placement Agent
Private Placement
July 2015
$40 Million
Joint Bookrunner
Follow-On
July 2015
$130 Million
Joint Bookrunner
Follow-On
July 2015
$282 Million
Joint Bookrunner
Follow-On
July 2015
€32 Million
Private Placement
Exclusive Placement Agent
July 2015
$212 Million
Financial Advisor
Acquisition of Celsis International
July 2015
$225 Million
Co-Manager
Initial Public Offering
June 2015
$103 Million
Co-Manager
Follow-On
June 2015
$276 Million
Co-Manager
Follow-On
June 2015
$230 Million
Joint Bookrunner
Follow-On
June 2015
$60 Million
Sole Placement Agent
Private Placement
June 2015
$48 Million
Joint Bookrunner
Initial Public Offering
June 2015
$137 Million
Joint Bookrunner
Follow-On
June 2015
$75 Million
Joint Bookrunner
Follow-On
June 2015
$78 Million
Sole Placement Agent
PIPE
June 2015
$1,290 Million
Co-Manager
Follow-On
May 2015
$35 Million
Joint Bookrunner
Follow-On
May 2015
$49 Million
Joint Bookrunner
Follow-On
May 2015
$25 Million
Sole Bookrunner
Follow-On
May 2015
$41 Million
Joint Bookrunner
Follow-On
May 2015
$50 Million
Sole Bookrunner
Initial Public Offering
May 2015
$191 Million
Joint Bookrunner
Initial Public Offering
May 2015
$76 Million
Joint Bookrunner
Follow-On
April 2015
$100 Million + Milestones
Exclusive Financial Advisor
Sale of Zohydro to Pernix
April 2015
$80 Million
Joint Bookrunner
Follow-On
April 2015
$137 Million
Joint Bookrunner
Initial Public Offering
April 2015
$77 Million
Joint Bookrunner
Initial Public Offering
April 2015
$89 Million
Joint Bookrunner
Follow-On
April 2015
$75 Million
Sole Bookrunner
Initial Public Offering
April 2015
$40 Million
Joint Bookrunner
Follow-On
April 2015
$98 Million
Joint Bookrunner
Follow-On
April 2015
Not Disclosed
Exclusive Financial Advisor
Merger with Uroplasty to create Cogentix Medical
March 2015
$238 Million
Joint Bookrunner
Follow-On
March 2015
$55 Million
Joint Bookrunner
Follow-On
March 2015
$285 Million
Co-Manager
Follow-On
March 2015
$64 Million
Joint Bookrunner
Follow-On
March 2015
$35 Million
Joint Bookrunner
Follow-On
March 2015
$152 Million
Joint Bookrunner
Follow-On
March 2015
$149 Million
Joint Bookrunner
Follow-On
March 2015
$139 Million
Joint Bookrunner
Follow-On
March 2015
$144 Million
Joint Bookrunner
Follow-On
March 2015
$58 Million
Lead Placement Agent
Private Placement & Reverse Merger
March 2015
$130 Million
Joint Bookrunner
Follow-On
March 2015
$192 Million
Joint Bookrunner
Follow-On
March 2015
$200 Million
Joint Bookrunner
Follow-On
February 2015
$123 Million
Sole Bookrunner
Follow-On
February 2015
$60 Million
Joint Bookrunner
Initial Public Offering
February 2015
$142 Million
Joint Bookrunner
Follow-On
February 2015
$117 Million
Co-Manager
Initial Public Offering
February 2015
$53 Million
Sole Bookrunner
Follow-On
January 2015
$52 Million
Joint Bookrunner
Follow-On
January 2015
$87 Million
Sole Bookrunner
Follow-On
January 2015
$124 Million
Joint Bookrunner
Initial Public Offering
January 2015
$138 Million
Joint Bookrunner
Follow-On
January 2015
$54 Million
Joint Bookrunner
Follow-On
January 2015
$5.2 Billion
Financial Advisor
Sale to Shire
January 2015
$204 Million
Joint Bookrunner
Follow-On
January 2015
$400 Million
Co-Manager
Convertible Senior Note Offering
January 2015
$84 Million
Joint Bookrunner
Follow-On
January 2015
$51 Million
Exclusive Placement Agent
Private Placement
January 2015
$145 Million
Co-Manager
Initial Public Offering
November 2014
$414 Million
Joint Bookrunner
Follow-On
November 2014
$168 Million
Joint Bookrunner
Initial Public Offering
November 2014
$199 Million
Co-Manager
Initial Public Offering
October 2014
$52 Million
Co-Manager
Follow-On
October 2014
$86 Million
Co-Manager
Initial Public Offering
October 2014
$133 Million
Joint Bookrunner
Follow-On
October 2014
$235 Million
Joint Bookrunner
Initial Public Offering
October 2014
$80 Million
Joint Bookrunner
Initial Public Offering
October 2014
$125 Million
Joint Bookrunner
Initial Public Offering
October 2014
$410 Million
Financial Advisor
Sale to Daiichi-Sankyo
September 2014
$1,025 Million
Lead Financial Advisor
Acquisition of Lumara Health Maternal Health Business
September 2014
$112 Million
Joint Bookrunner
Initial Public Offering
September 2014
$56 Million
Joint Bookrunner
Initial Public Offering
September 2014
Not Disclosed
Exclusive Financial Advisor
Sale to Cynosure
September 2014
$51 Million
Exclusive Placement Agent
Series C Private Placement
August 2014
$115 Million
Sole Bookrunner
Follow-On
August 2014
$325 Million
Co-Manager
Convertible Senior Notes
August 2014
$66 Million
Co-Manager
Initial Public Offering
August 2014
$134 Million
Exclusive Financial Advisor
Series B Private Placement
August 2014
$61 Million
Joint Bookrunner
Initial Public Offering
August 2014
$105 Million
Exclusive Financial Advisor
Sale to Medtronic
July 2014
$63 Million
Co-Manager
Initial Public Offering
July 2014
$65 Million
Joint Bookrunner
Initial Public Offering
July 2014
$60 Million
Joint Bookrunner
Initial Public Offering
July 2014
$42 Million
Joint Bookrunner
Initial Public Offering
July 2014
$70 Million
Sole Financial Advisor
Convertible Notes & Amended Loan Agreement with HealthCare Royalty Partners
July 2014
Not Disclosed
Exclusive Financial Advisor
Merger with Paratek
July 2014
$129 Million
Joint Bookrunner
Follow-On
June 2014
$63 Million
Joint Bookrunner
Follow-On
June 2014
€50 Million
Co-Placement Agent
Private Placement
June 2014
$110 Million
Joint Bookrunner
Initial Public Offering
June 2014
$69 Million
Joint Bookrunner
Initial Public Offering
June 2014
$205 Million
Joint Bookrunner
Follow-On
June 2014
$34 Million
Exclusive Placement Agent
Private Placement
June 2014
$88 Million
Joint Bookrunner
Initial Public Offering
May 2014
$1,495 Million
Co-Manager
Initial Public Offering
April 2014
$170 Million
Exclusive Financial Advisor
Sale to The Medicines Company
April 2014
€42 Million
Exclusive Placement Agent
Private Placement
April 2014
$36 Million
Financial Advisor & Placement Agent
Merger & Series B Financing
April 2014
$60 Million
Sole Bookrunner
Initial Public Offering
April 2014
$62 Million
Joint Bookrunner
Follow-On
April 2014
$55 Million
Joint Bookrunner
Initial Public Offering
April 2014
$179 Million
Financial Advisor
Acquisition of Galapagos' Services Division
March 2014
$55 Million
Sole Bookrunner
Follow-On
March 2014
$61 Million
Sole Manager
Follow-On
March 2014
$27 Million
Exclusive Placement Agent
Series B Private Placement
March 2014
$84 Million
Sole Advisor
Acquisition of Ex-North America Rights from Bayer Consumer Care AG
March 2014
$50 Million
Sole Bookrunner
Follow-On
March 2014
$35 Million
Exclusive Placement Agent
Private Financing
February 2014
$72 Million
Co-Manager
Initial Public Offering
February 2014
$94 Million
Co-Manager
Follow-On
February 2014
NOT DISCLOSED
Exclusive Financial Advisor
Sale to Stryker
February 2014
$52 Million
Lead Placement Agent
Private Placement
February 2014
$126 Million
Joint Bookrunner
Follow-On
February 2014
$138 Million
Joint Bookrunner
Follow-On
February 2014
$58 Million
Joint Bookrunner
Initial Public Offering
February 2014
$151 Million
Joint Bookrunner
Follow-On
February 2014
$92 Million
Joint Bookrunner
Initial Public Offering
February 2014
$124 Million
Joint Bookrunner
Follow-On
January 2014
$104 Million
Joint Bookrunner
Initial Public Offering
January 2014
$101 Million
Joint Bookrunner
Follow-On
January 2014
$61 Million
Co-Manager
Follow-On
January 2014
$138 Million
Joint Bookrunner
Follow-On
January 2014
$75 Million
Sole Advisor
Global Strategic Partnership with Valeant Pharmaceuticals
January 2014
$117 Million
Joint Bookrunner
Follow-On
January 2014
$34M+ $26M Milestones
Exclusive Financial Advisor
Sale to AtriCure, Inc.
December 2013
Not Disclosed
Exclusive Financial Advisor
Global License & Option Agreement with Takeda Pharmaceutical Co. Ltd.
December 2013
$155M + $1.8B Milestones
Exclusive Financial Advisor
Collaboration with Celgene
December 2013
$197 Million
Joint Bookrunner
Follow-On
December 2013
$115 Million
Joint Bookrunner
Convertible Debt
December 2013
$81 Million
Joint Bookrunner
Initial Public Offering
December 2013
$90 Million
Co-Manager
Follow-On
November 2013
$62 Million
Joint Bookrunner
Follow-On
November 2013
$125 Million
Joint Bookrunner
Initial Public Offering
November 2013
$69 Million
Joint Bookrunner
Follow-On
November 2013
$66 Million
Joint Bookrunner
Initial Public Offering
October 2013
$58 Million
Joint Bookrunner
Follow-On
October 2013
$92 Million
Joint Bookrunner
Initial Public Offering
October 2013
$134 Million
Joint Bookrunner
Follow-On
October 2013
$35 Million
Sole Bookrunner
Follow-On
September 2013
$122 Million
Co-Manager
Initial Public Offering
September 2013
$96 Million
Joint Bookrunner
Initial Public Offering
September 2013
$410 Million
Exclusive Financial Advisor
Sale to Catamaran Corp
August 2013
Not Disclosed
Exclusive Financial Advisor
Sale to Cardinal Health
August 2013
$65 Million
Joint Bookrunner
Follow On
August 2013
$201 Million
Joint Bookrunner
Follow-On
August 2013
$72 Million
Sole Bookrunner
Follow On
July 2013
$89 Million
Joint Bookrunner
Initial Public Offering
July 2013
$46 Million
Co-Manager
Initial Public Offering
July 2013
$64 Million
Joint Bookrunner
Follow On
July 2013
$94 Million
Joint Bookrunner
Initial Public Offering
July 2013
$54 Million
Co-Manager
Initial Public Offering
June 2013
Not Disclosed
Exclusive Financial Advisor
Staged Sale to St. Jude Medical
June 2013
Not Disclosed
Exclusive Financial Advisor
In-licensing of commercial rights to MuGard from Access Pharmaceuticals
June 2013
$89 Million
Joint Bookrunner
Initial Public Offering
May 2013
Not Disclosed
Exclusive Financial Advisor
Sale of Transactional Business to GE Healthcare
May 2013
$55 Million
Exclusive Placement Agent
Private Placement
May 2013
$65 Million
Joint Bookrunner
Initial Public Offering
May 2013
$83 Million
Joint Bookrunner
Initial Public Offering
May 2013
$110 Million
Exclusive Financial Advisor
Sale to Jawbone
April 2013
$64 Million
Joint Bookrunner
Initial Public Offering
April 2013
$24 Million
Exclusive Financial Advisor
Sale to / Simultaneous Financing TranS1 Inc.
March 2013
$35 Million
Lead Placement Agent
PIPE
March 2013
$294 Million
Exclusive Financial Advisor
Acquisition of Palomar Medical Technologies
March 2013
$40 Million
Sole Bookrunner
Follow-On
March 2013
$69 Million
Joint Bookrunner
Follow-On
March 2013
$30 Million
Exclusive Placement Agent
Private Placement
February 2013
$142 Million
Joint Bookrunner
Follow-On
February 2013
$104 Million
Joint Bookrunner
Follow-On
February 2013
$70 Million
Sole Bookrunner
Initial Public Offering
January 2013
$83 Million
Exclusive Financial Advisor
Sale to Analogic Corporation
January 2013
Not Disclosed
Exclusive Financial Advisor
Sale of fiXate Tissue Band Assets to Boston Scientific
January 2013
$34 Million
Joint Bookrunner
Follow-On
January 2013
Not Disclosed
Exclusive Financial Advisor
Strategic Investment From Merck Global Health Innovation
December 2012
Not Disclosed
Financial Advisor
Strategic Investment From GE Healthymagination
December 2012
$115M + Option to Purchase
Exclusive Financial Advisor
Collaboration with BMS for Recothrom Bristol-Myers Squibb
December 2012
$185M + Und. Earnout
Exclusive Financial Advisor
Sale to The Medicines Company
December 2012
$50 Million
Financial Advisor
Royalty Financing Agreement with HealthCare Royalty Partners
December 2012
Not Disclosed
Financial Advisor
Sale to KCI
November 2012
$230 Million
Exclusive Financial Advisor
Sale to Sun Pharmaceutical Industries
November 2012
$210 Million
Co-Lead Placement Agent
Private Placement
November 2012
$75 Million
Sole Bookrunner
Follow-On
November 2012
$61 Million
Joint Bookrunner
Follow-On
October 2012
$138 Million
Joint Bookrunner
Follow-On
October 2012
Undisclosed
Financial Advisor
Minority Recap with West End Holdings & Clayton Associates
September 2012
$110 Million
Exclusive Financial Advisor
Sale to McKesson
September 2012
$60 Million
Co-Manager
Follow-On
August 2012
$115 Million
Joint Bookrunner
Initial Public Offering
August 2012
Not Disclosed
Exclusive Financial Advisor
Sale to Life Technologies
July 2012
$58 Million
Joint Bookrunner
Initial Public Offering
July 2012
$38 Million
Joint Bookrunner
Follow-On
July 2012
$20 Million
Joint Bookrunner
Follow-On
June 2012
$87 Million
Joint Bookrunner
Initial Public Offering
June 2012
Not Disclosed
Exclusive Financial Advisor
Collaboration Agreement with Roche
June 2012
$30M + $50M Earnout
Exclusive Financial Advisor
Sale to Teleflex
June 2012
$16 Million
Sole Bookrunner
Follow-On
May 2012
$41 Million
Joint Bookrunner
Follow-On
April 2012
$60 Million
Joint Bookrunner
Follow-On
April 2012
$43 Million
Lead Placement Agent
Private Placement
April 2012
$108 Million
Co-Manager
Initial Public Offering
March 2012
$57 Million
Joint Bookrunner
Follow-On
March 2012
$66 Million
Joint Bookrunner
Follow-On
March 2012
$60 Million
Joint Bookrunner
Follow-On
February 2012
$58 Million
Joint Bookrunner
Initial Public Offering
February 2012
$63 Million
Joint Bookrunner
Initial Public Offering
January 2012
$50 Million
Joint Bookrunner
Follow-On
January 2012
$24 Million
Sole Bookrunner
Follow-On
January 2012
$16 Million
Sole Bookrunner
Follow-On
December 2011
$90 Million
Sole Bookrunner
Follow-On
December 2011
$37 Million
Sole Financial Advisor
Series D Financing
November 2011
$60 Million
Joint Bookrunner
Follow-On
September 2011
$82 Million
Joint Bookrunner
Follow-On
July 2011
$52 Million
Joint Bookrunner
Follow-On
July 2011
$75M + $200M Earnout
Financial Advisor
Sale to Allergan
July 2011
$65 Million
Joint Bookrunner
Follow-On
June 2011
$518 Million
Co-Manager
Initial Public Offering
June 2011
UNDISCLOSED
Financial Advisor
Acquisition of Aesthetic Business of HOYA ConBio
June 2011
$32 Million
Financial Advisor
Royalty Financing Agreement with HealthCare Royalty Partners
June 2011
Not Disclosed
Financial Advisor
Sale of Parallax Assets to Neurotherm
June 2011
$58 Million
Joint Bookrunner
Follow-On
June 2011
Not Disclosed
Financial Advisor
Sale of Assets to Sedgwick CMS
May 2011
$114 Million
Joint Bookrunner
Follow-On
April 2011
$4.4 Billion
Co-Manager
Initial Public Offering
March 2011
$86 Million
Co-Manager
Initial Public Offering
February 2011
$86 Million
Joint Bookrunner
Initial Public Offering
February 2011
$45 Million
Joint Bookrunner
Follow-On
January 2011
$50 Million
Joint Bookrunner
Follow-On
January 2011
$105 Million
Joint Bookrunner
Follow-On
January 2011
$58 Million
Joint Bookrunner
Initial Public Offering
November 2010
$55 Million
Joint Bookrunner
Initial Public Offering
October 2010
Not Disclosed
Exclusive Financial Advisor
Acquisition of Discus Dental
October 2010
$50 Million
Joint Bookrunner
Initial Public Offering
August 2010
$2.5 Billion
Co-Manager
Convertible Debt
July 2010
$85M + $250M Earnout
Financial Advisor
Sale to Hologic
July 2010
$105 Million
Exclusive Financial Advisor
Acquisition of Helixis
July 2010
$329 Million
Financial Advisor
Sale to Covidien
June 2010
$30 Million
Joint Bookrunner
Initial Public Offering
April 2010
$99 Million
Joint Bookrunner
Follow-On
March 10
$34 Million
Sole Bookruner
Follow-On
January 2010
$130 Million
Financial Advisor
Acquisition of Diagnostic Hybrids
January 2010
$97 Million
Sole Bookrunner
Follow-On
January 2010
$29 Million
Financial Advisor
Sale to Sciele (A Shionogi Company)
November 2009
$199 Million
Joint Bookrunner
Initial Public Offering
October 2009
$85 MILLION
Financial Advisor
Sale to Gen-Probe
October 2009
$49 Million
Sole Bookrunner
Follow-On
September 2009
$288 Million
Financial Advisor
Sale to Leo Pharma
September 2009
$68 Million
Financial Advisor
Merger with Candela
September 2009
$398 Million
Financial Advisor
Tender Offer to Acquire Facet Biotech
September 2009
$50 Million
Sole Agent
Private Placement
September 2009
$23 Million
Sole Bookrunner
Follow-On
August 2009
$86 Million
Sole Bookrunner
Follow-On
July 2009
$1.0 Billion
Financial Advisor
Fairness Opinion in Sale to Johnson & Johnson
May 2009